查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829022

癌症免疫療法市場按治療類型、作用機制、治療方向、給藥途徑、適應症和最終用戶分類－2025-2032 年全球預測

Cancer Immunotherapy Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Route Of Administration, Indication, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症免疫治療市場規模將成長至 1,207.5 億美元，複合年成長率為 5.71%。

主要市場統計數據
基準年2024年 773.9億美元
預計2025年 817.4億美元
預測年份：2032年 1207.5億美元
複合年成長率（%） 5.71%

癌症免疫療法發展的基本概述，重點介紹臨床進展、營運挑戰以及相關人員的策略要務

在持續的臨床進展和監管里程碑的推動下，癌症免疫療法已從一個充滿希望的科學概念轉變為癌症治療的核心支柱。在過去十年中，利用免疫系統的治療方法重新定義了骨髓惡性腫瘤和越來越多的固體癌的治療模式，並在許多患者亞群中產生了有意義且持久的療效。這一演變是由多種技術進步的融合所推動的，包括細胞工程、精準生物標記檢測以及不斷擴展的單株抗體、疫苗和病毒載體庫。

隨著研究的不斷成熟，學術界和產業界的臨床相關人員面臨新的營運和策略挑戰。研發人員必須在組合方案的科學複雜性與生產個人化產品的物流需求之間取得平衡，而支付者和醫療系統也日益要求提供長期價值和可控治療途徑的證據。因此，規劃該領域治療方案和服務的組織必須將轉化科學與供應鏈彈性、監管協調和患者可及性模式等實際考量相結合，以實現規模化的臨床效益。

本執行摘要整合了當前的動態、監管和商業阻力，以及相關人員可以採取的可行步驟，以應對不斷變化的競爭和臨床格局。其目標是提供清晰的、以證據為導向的敘述，以支持決策制定，同時又不掩蓋腫瘤生物學、治療方法或醫療服務環境的多樣性。

影響免疫腫瘤學的關鍵轉型趨勢，包括技術創新、個人化策略和整個價值鏈的營運現代化

在科學突破、監管調整和相關人員期望不斷變化等因素的共同推動下，癌症免疫療法領域正在發生重大變革。首先，細胞療法，尤其是嵌合體抗原受體T細胞成熟療法，正從最初在血液學適應症中的成功應用，拓展到合成構建體和同種異體療法，旨在擴大其應用範圍並縮短治療持續時間。查核點抑制技術的同步進展與更精細的免疫調節方法相輔相成，包括雙特異性分子和旨在改善特異性和毒性特徵的新一代抗體形式。

其次，轉化科學正在加速個人化治療方案的發展，例如新抗原疫苗、腫瘤浸潤淋巴細胞最佳化以及基於生物標記的多重檢測。因此，將臨床專業知識與診斷和生物資訊能力相結合的合作研究至關重要。第三，製造和供應鏈創新，包括自動化、封閉式系統處理和區域化生產基地，正在改變開發商的規模化和商業化規劃方式，雖然減少了一些障礙，但也帶來了新的資本和監管複雜性。

第四，動態和付款方的動態正在影響治療方法的評估方式，尤其強調長期療效、基於價值的合約以及醫療體系的整合。單靠科學新穎性是不夠的，還需要可靠的開發路徑、強大的營運執行力以及以付款方為導向的證據產生。這些因素的結合將決定哪些項目能夠從臨床前景走向永續的臨床和商業性影響。

評估 2025 年不斷變化的關稅政策將如何改變免疫療法相關人員的供應鏈、製造策略和商業性定位

美國新關稅政策的實施將持續到2025年，這可能對整個免疫腫瘤學生態系統產生累積影響，改變成本、供應鏈配置和採購決策。生物製藥製劑和細胞療法生產所需的專用試劑、一次性耗材、生物加工設備和低溫運輸物流服務通常在全球範圍內採購。進口關稅的提高和海關摩擦可能會增加到岸成本，促使企業進行庫存審查，並加快尋找替代供應商的努力。這可能會導致採購前置作業時間延長，並給研發計畫帶來壓力，因為應急計畫已成為專案風險管理的關鍵組成部分。

為了應對關稅帶來的成本壓力，許多相關人員可能會尋求近岸外包或國內製造夥伴關係，以減少跨境貿易波動帶來的風險，並維持對關鍵生產過程的控制。雖然這種策略轉變可能會增加前期投資負擔，但也可能在供應連續性和法律規範方面帶來長期效益。此外，不斷上升的投入成本將促使人們更加嚴格地審查製造效率、製程集約化和產量比率最佳化，從而推動對自動化、封閉式系統和數位監控的投資，以在維持品質的同時保護淨利率。

最後，關稅變化的累積影響可能會影響商業策略，包括價格談判、付款人合約以及產品發布時機。積極審查供應商關係、優先考慮彈性生產路徑並向付款人透明地展示成本及其產生的價值的組織，將更有能力在受關稅影響的市場環境中減輕財務和營運中斷的影響。

綜合細分分析突顯了治療方式、機制、適應症和護理環境的不同發展和商業化路徑

細緻的細分框架揭示了臨床差異化和商業性機會在治療類型、機制、治療線、給藥途徑、適應症和最終用戶之間的交集。按治療類型分類，項目包括癌症疫苗、CAR-T 療法、CTLA-4 抑制劑、溶瘤病毒療法、PD-1 抑制劑和 PD-L1 抑制劑，每種方案都考慮不同的開發挑戰和臨床定位。疫苗策略強調抗原選擇和遞送平台，而細胞療法則需要製造創新和以患者為中心的物流。根據作用機制，該領域包括過繼性細胞轉移、查核點抑制劑、細胞激素療法、溶瘤病毒療法和疫苗療法。這種機制多樣性需要客製化生物標記策略、安全監測框架和組合假設，以在控制毒性的同時最大限度地提高療效。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合單細胞定序數據以識別新型腫瘤抗原，用於個人化免疫治療
  • 針對固態腫瘤微環境的基因編輯增強CAR-T細胞治療進展
  • 新興的微生物組調節策略可提高查核點抑制劑的反應率
  • 引入人工智慧驅動的預測性生物標記物，用於早期評估患者對免疫療法的反應
  • 開發包含安全開關機制的現成同種異體 NK 細胞療法
  • 溶瘤病毒與免疫查核點抑制劑合併治療難治性癌症

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 癌症免疫治療市場（依治療類型）

  • 癌症疫苗
  • CAR-T療法
  • CTLA-4抑制劑
  • 溶瘤病毒療法
  • PD-1抑制劑
  • PD-L1抑制劑

第9章 癌症免疫治療市場（依作用機轉）

  • 過繼細胞移植
  • 查核點抑制劑
  • 細胞激素治療
  • 溶瘤病毒療法
  • 疫苗治療

第 10 章：癌症免疫療法市場治療線

  • 第一行
  • 從第四行開始
  • 第二行
  • 第三行

第11章 癌症免疫治療市場（依給藥途徑）

  • 腫瘤內
  • 靜脈
  • 皮下

第12章 癌症免疫治療市場（按適應症）

  • 造血系統惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固態腫瘤
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 黑色素瘤

第13章 癌症免疫治療市場（按最終用戶）

  • 醫院
  • 研究機構
  • 專科診所

第14章 癌症免疫治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 癌症免疫治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 癌症免疫治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • AstraZeneca PLC
    • Pfizer Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Sanofi SA
    • Gilead Sciences, Inc.
Product Code: MRR-4330CC794A6B

The Cancer Immunotherapy Market is projected to grow by USD 120.75 billion at a CAGR of 5.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 77.39 billion
Estimated Year [2025] USD 81.74 billion
Forecast Year [2032] USD 120.75 billion
CAGR (%) 5.71%

Foundational overview of cancer immunotherapy evolution highlighting clinical progress, operational challenges, and strategic imperatives for stakeholders

Cancer immunotherapy has moved from a promising scientific concept to a central pillar of oncology care, driven by a sustained wave of clinical advances and regulatory milestones. Over the past decade, therapies that harness the immune system have redefined treatment paradigms for both hematologic malignancies and a growing set of solid tumors, creating meaningful durable responses for many patient subgroups. This evolution has been propelled by a convergence of technological improvements in cell engineering, precision biomarker assays, and an expanding repertoire of monoclonal antibodies, vaccines, and viral vectors.

As research continues to mature, stakeholders across industry, academia, and clinical practice face a new set of operational and strategic questions. Developers must balance the scientific complexity of combination regimens with the logistical demands of manufacturing personalized products, while payers and health systems increasingly seek evidence of long-term value and manageable treatment pathways. Consequently, organizations planning therapeutics or services in this space must integrate translational science with pragmatic considerations such as supply chain resilience, regulatory alignment, and patient access models to realize clinical benefit at scale.

This executive summary synthesizes current dynamics, regulatory and commercial headwinds, and actionable avenues for stakeholders to navigate the changing competitive and clinical environment. The goal is to offer a clear, evidence-aligned narrative that supports decision-making without obscuring the heterogeneity of tumor biology, therapeutic modalities, or care delivery contexts.

Critical transformative trends reshaping immuno-oncology including technological innovation, personalized strategies, and operational modernization across the value chain

The landscape of cancer immunotherapy is undergoing transformative shifts driven by a combination of scientific breakthroughs, regulatory adaptations, and evolving stakeholder expectations. First, the maturation of cell therapies, particularly chimeric antigen receptor T cells, has expanded beyond early successes in hematologic indications toward engineered constructs and allogeneic approaches designed to broaden applicability and reduce time-to-treatment. Parallel advances in checkpoint inhibition have been complemented by more nuanced approaches to immune modulation, including bispecific molecules and next-generation antibody formats that seek improved specificity and toxicity profiles.

Second, translational science is accelerating personalized approaches-neoantigen vaccines, tumor-infiltrating lymphocyte optimization, and multiplexed biomarker-driven trials-that demand more intricate trial designs and real-world evidence capture. As a result, collaborations that pair clinical expertise with diagnostic and bioinformatics capabilities are becoming essential. Third, manufacturing and supply chain innovations, including automation, closed-system processing, and regionalized production hubs, are shifting how developers plan scale-up and commercialization, reducing some barriers but introducing new capital and regulatory complexities.

Fourth, market and payer dynamics are influencing how therapies are evaluated, with a pronounced emphasis on long-term outcomes, value-based contracting, and healthcare system integration. Collectively, these shifts are redefining competitive advantage: scientific novelty alone is insufficient without credible development pathways, robust operational execution, and payer-aligned evidence generation. The combination of these elements will determine which programs progress from clinical promise to sustainable clinical and commercial impact.

Assessment of how evolving tariff policies in 2025 could alter supply chains, manufacturing strategies, and commercial positioning across immunotherapy stakeholders

The introduction of new tariff policies in the United States during 2025 has the potential to exert a cumulative impact across the cancer immunotherapy ecosystem by altering costs, supply chain configurations, and sourcing decisions. Key inputs for biologic and cell therapy manufacturing-specialized reagents, single-use consumables, bioprocessing equipment, and cold-chain logistics services-are often sourced globally. An increase in import duties or customs friction can elevate landed costs, prompt inventory rebalancing, and accelerate efforts to qualify alternative suppliers. Consequently, research and development timelines may experience pressure as procurement lead times extend and contingency planning becomes a material component of program risk management.

In response to tariff-driven cost pressures, many stakeholders may pursue nearshoring or domestic manufacturing partnerships to reduce exposure to cross-border trade volatility and maintain control over critical production steps. Such strategic reorientation could increase upfront capital deployment but may also yield long-term advantages in supply continuity and regulatory oversight. Moreover, higher input costs will heighten scrutiny of manufacturing efficiency, process intensification, and yield optimization, incentivizing investments in automation, closed systems, and digital monitoring to protect margins while preserving quality.

Finally, the cumulative effects of tariff changes will likely influence commercial strategies including pricing negotiations, payer contracting, and the staging of product launches. Organizations that proactively reassess supplier relationships, prioritize resilient manufacturing pathways, and transparently demonstrate cost and outcome value to payers will be better positioned to mitigate financial and operational disruption in a tariff-influenced market environment.

Comprehensive segmentation analysis revealing where therapeutic modalities, mechanisms, indications, and care settings create distinct development and commercialization pathways

A nuanced segmentation framework illuminates where clinical differentiation and commercial opportunity intersect across therapy types, mechanisms, lines of therapy, administration routes, indications, and end users. Based on Therapy Type, programs span Cancer Vaccines, CAR-T Therapy, CTLA-4 Inhibitors, Oncolytic Virus Therapy, PD-1 Inhibitors, and PD-L1 Inhibitors, each presenting distinct development challenges and clinical positioning considerations; vaccine strategies emphasize antigen selection and delivery platforms, whereas cell therapies demand manufacturing innovation and patient-centric logistics. Based on Mechanism Of Action, the field encompasses Adoptive Cell Transfer, Checkpoint Inhibitors, Cytokine Therapy, Oncolytic Virus Therapy, and Vaccine Therapy, and this mechanistic diversity requires tailored biomarker strategies, safety monitoring frameworks, and combination hypotheses to maximize efficacy while managing toxicity.

Based on Line Of Therapy, therapeutic opportunities and payer expectations vary significantly between First Line, Second Line, Third Line, and Fourth Line And Beyond, with earlier-line approvals necessitating higher-evidence thresholds and clearer comparative benefit; consequently, developers should plan sequencing strategies that align trial design with expected reimbursement scenarios. Based on Route Of Administration, distinctions among Intratumoral, Intravenous, and Subcutaneous approaches influence clinical workflow, patient burden, and site-of-care economics, shaping adoption pathways across hospitals and clinics. Based on Indication, the landscape bifurcates into Hematologic Malignancies and Solid Tumors, with the former further segmented into Leukemia, Lymphoma, and Multiple Myeloma and the latter into Breast Cancer, Colorectal Cancer, Lung Cancer, and Melanoma, each indication presenting unique tumor microenvironmental considerations and biomarker profiles that inform patient selection and combination strategies.

Based on End User, hospitals, research institutes, and specialty clinics play differentiated roles in clinical trial accrual, product administration, and post-market evidence generation; hospitals often lead high-complexity administrations and inpatient monitoring, research institutes drive translational science and early-phase innovation, while specialty clinics enable outpatient delivery models that can improve throughput and patient convenience. Together, this segmentation highlights where scientific focus, operational investment, and commercial engagement should be concentrated to address unmet needs and optimize development trajectories.

Region-specific dynamics and strategic considerations for regulatory engagement, evidence generation, and manufacturing across global immunotherapy markets

Regional dynamics shape clinical trial design, regulatory engagement, manufacturing investment, and access strategies, demanding region-specific approaches that accommodate regulatory frameworks, reimbursement systems, and healthcare infrastructure. In the Americas, regulatory agencies and payers emphasize robust outcomes evidence and real-world data, while large research networks and venture and corporate investment have accelerated first-in-human studies and commercialization pathways; consequently, organizations often prioritize North American clinical validation and payer dialogue early in development to underpin broader market access plans. The Americas also host concentrated manufacturing and logistics capabilities, which supports rapid scale-up but requires careful coordination with hospital and specialty clinic administration models.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement environments necessitate multi-jurisdictional regulatory strategies and differentiated pricing approaches. European health technology assessment bodies place particular weight on comparative effectiveness and cost-effectiveness assessments, influencing trial endpoints and evidence generation plans. Additionally, emerging markets across the Middle East & Africa present opportunities for capacity building and pilot access programs but require tailored operational partnerships and investment in cold-chain and training infrastructure.

In Asia-Pacific, accelerated trial recruitment, growing biotech innovation hubs, and increasing local manufacturing capacity are shaping regional strategies; countries in the region vary in regulatory timelines and local clinical expectations, prompting companies to calibrate development plans to leverage speed to data while ensuring quality and regulatory alignment. Cross-region collaboration, such as bridging studies and harmonized regulatory submissions, can reduce time-to-patient access and support global labeling strategies, provided sponsors anticipate regional clinical practice patterns and payer requirements.

Competitive dynamics and partnership-based strategies revealing how execution, manufacturing scale, and platform differentiation drive long-term value creation

The competitive landscape is characterized by incumbent immuno-oncology leaders and a large cohort of emerging biotechs pursuing platform innovation, niche indications, or combination regimens. Established developers have leveraged deep clinical datasets and manufacturing footprints to secure broad label expansions and to negotiate value-based arrangements with payers, whereas smaller firms often focus on differentiated biology, novel antigen targets, or enabling technologies that improve manufacturability and patient access.

Across the ecosystem, strategic partnerships between developers, contract development and manufacturing organizations, diagnostic providers, and academic centers have become increasingly common as a means to accelerate clinical translation and de-risk capital-intensive steps. These alliances frequently address discrete gaps such as vector manufacturing, T-cell engineering, or companion diagnostic validation, enabling faster trial starts and improved operational scalability. In parallel, service providers offering automation, analytics, and patient management tools are emerging as critical enablers for both personalized and standardized therapeutic approaches.

Intellectual property positioning, clinical differentiation, and demonstrated ability to execute complex supply chains remain decisive factors in value creation. Firms that combine robust clinical programs with scalable manufacturing, payer-aligned evidence strategies, and strong collaborative networks will retain strategic advantage. At the same time, new entrants that deliver platform-level improvements in safety, cost, or ease-of-use can rapidly gain relevance through licensing or co-development agreements.

Actionable strategic recommendations for aligning clinical development, manufacturing resilience, and payer engagement to accelerate adoption and value realization

Leaders planning to navigate the next phase of immuno-oncology advancement should adopt integrated strategies that align science, operations, and commercialization. First, prioritize modular development plans that allow for adaptive trial designs and biomarker-enriched cohorts to demonstrate meaningful benefit while preserving flexibility for label expansion and combinations. Early engagement with regulatory bodies and payers is essential to define clinically relevant endpoints and acceptable evidence packages that support durable reimbursement outcomes. Second, invest in manufacturing resilience by exploring regional production hubs, automation, and supplier diversification to mitigate geopolitical and tariff-related disruption while maintaining quality and compliance standards.

Third, cultivate strategic partnerships spanning diagnostics, contract manufacturing, and clinical network collaborators to accelerate translational pathways and reduce time-to-patient. By leveraging external expertise, organizations can focus internal resources on core differentiators such as target biology and clinical execution. Fourth, design patient-centric delivery models that reduce burden, enable outpatient administration where feasible, and integrate digital tools for monitoring and outcomes capture. These models enhance adherence and produce real-world evidence that reinforces payer negotiations and clinical adoption.

Finally, maintain disciplined portfolio management that balances novel, high-risk science with programs offering clearer paths to clinical and commercial viability. Establishing cross-functional governance for prioritization, risk monitoring, and go-to-market readiness will enable faster, more confident decisions as the scientific and policy environment evolves.

Robust multi-source research methodology integrating expert interviews, regulatory analysis, and operational assessments to generate actionable industry insights

The research synthesis draws on a multi-source methodology designed to integrate scientific literature, regulatory guidance, expert interviews, and operational insights to build a coherent narrative aligned with industry practice. Primary qualitative inputs included structured interviews with clinical investigators, manufacturing leads, payers, and commercial strategists to surface pragmatic barriers and enablers across development and delivery pathways. These interviews were complemented by a systematic review of peer-reviewed publications, regulatory approvals, and public filings to ensure the analysis reflects recent scientific advances and policy shifts.

Additionally, the methodology incorporated operational assessments of manufacturing and supply chain considerations through engagements with contract development and manufacturing organizations and logistics specialists. This allowed for an informed appraisal of practical constraints such as lead times, cold-chain requirements, and capacity scaling. Analytical synthesis emphasized cross-validation, pairing qualitative perspectives with documented clinical and regulatory milestones to reduce bias and enhance actionability. Throughout the research process, attention was paid to transparency of assumptions, the provenance of insights, and the identification of areas where further primary data collection could refine conclusions.

This multi-dimensional approach enables stakeholders to interpret findings in the context of their own strategic priorities while recognizing the heterogeneity inherent in therapeutic modalities, geographic markets, and care delivery models.

Concluding synthesis emphasizing the necessity of integrated scientific, operational, and commercial strategies to realize the full promise of immuno-oncology

Cancer immunotherapy stands at an inflection point where scientific progress must be matched by operational excellence and strategic clarity to sustain momentum. Novel modalities and combination strategies continue to expand the therapeutic toolkit, but their ultimate impact will depend on the ability of stakeholders to navigate complex manufacturing requirements, diverse regulatory expectations, and evolving payer evidence demands. Organizations that proactively adapt development strategies to incorporate biomarker-driven patient selection, resilient supply chains, and payer-aligned evidence will be better positioned to translate clinical promise into durable patient benefit.

Moreover, the growing interplay between regional regulatory environments and global commercialization strategies underscores the necessity of harmonized evidence plans and flexible manufacturing footprints. As new policy and trade dynamics emerge, including tariff considerations, the capacity to rapidly adjust sourcing and production approaches becomes a competitive advantage. In conclusion, the path forward requires integrated leadership across science, operations, and commercial functions to ensure that innovations in immuno-oncology are delivered efficiently, equitably, and with demonstrable value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of single-cell sequencing data to identify novel tumor antigens for personalized immunotherapy
  • 5.2. Advancement in gene editing-enhanced CAR T-cell therapies targeting solid tumor microenvironment
  • 5.3. Emergence of microbiome modulation strategies to improve checkpoint inhibitor response rates
  • 5.4. Adoption of AI-driven predictive biomarkers for early assessment of patient response to immunotherapy
  • 5.5. Development of off-the-shelf allogeneic NK cell therapies with engineered safety switch mechanisms
  • 5.6. Combination approaches leveraging oncolytic viruses and immune checkpoint blockade for resistant cancers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Immunotherapy Market, by Therapy Type

  • 8.1. Cancer Vaccines
  • 8.2. CAR-T Therapy
  • 8.3. CTLA-4 Inhibitors
  • 8.4. Oncolytic Virus Therapy
  • 8.5. PD-1 Inhibitors
  • 8.6. PD-L1 Inhibitors

9. Cancer Immunotherapy Market, by Mechanism Of Action

  • 9.1. Adoptive Cell Transfer
  • 9.2. Checkpoint Inhibitors
  • 9.3. Cytokine Therapy
  • 9.4. Oncolytic Virus Therapy
  • 9.5. Vaccine Therapy

10. Cancer Immunotherapy Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line And Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Cancer Immunotherapy Market, by Route Of Administration

  • 11.1. Intratumoral
  • 11.2. Intravenous
  • 11.3. Subcutaneous

12. Cancer Immunotherapy Market, by Indication

  • 12.1. Hematologic Malignancies
    • 12.1.1. Leukemia
    • 12.1.2. Lymphoma
    • 12.1.3. Multiple Myeloma
  • 12.2. Solid Tumors
    • 12.2.1. Breast Cancer
    • 12.2.2. Colorectal Cancer
    • 12.2.3. Lung Cancer
    • 12.2.4. Melanoma

13. Cancer Immunotherapy Market, by End User

  • 13.1. Hospitals
  • 13.2. Research Institutes
  • 13.3. Specialty Clinics

14. Cancer Immunotherapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Immunotherapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Immunotherapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Merck & Co., Inc.
    • 17.3.2. Bristol-Myers Squibb Company
    • 17.3.3. F. Hoffmann-La Roche Ltd
    • 17.3.4. Novartis AG
    • 17.3.5. AstraZeneca PLC
    • 17.3.6. Pfizer Inc.
    • 17.3.7. Johnson & Johnson
    • 17.3.8. Amgen Inc.
    • 17.3.9. Sanofi S.A.
    • 17.3.10. Gilead Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLIO